Roy G Geronemus1, David E Bank, Bhushan Hardas, Ava Shamban, Barry M Weichman, Diane K Murphy. 1. *Laser & Skin Surgery Center of New York, New York, New York; †The Center for Dermatology, Cosmetic & Laser Surgery, Mt. Kisco, New York; ‡Allergan plc, Irvine, California; §AVA MD, Santa Monica, California; ‖BMW Associates, Monroe Township, New Jersey.
Abstract
BACKGROUND:VYC-15L (Juvéderm Volbella XC) is a nonanimal crosslinked hyaluronic acid (HA) gel with lidocaine. OBJECTIVE: To evaluate the safety and effectiveness of VYC-15L for lip and perioral enhancement versus a nonanimal stabilized HA with lidocaine (Restylane-L; NASHA). METHODS: This prospective multicenter study randomized 225 adults with minimal, mild, or moderate lip fullness on the validated 5-pointAllergan Lip Fullness Scale (LFS) to treatment with VYC-15L or NASHA; optional touch-up was administered 30 days later. Subjects were followed for 1 year. The primary effectiveness end point was noninferiority of VYC-15L versus NASHA by mean change in LFS score from baseline to Month 3. RESULTS: The primary end point was met. At Month 3, LFS responder rates were 80.3% for VYC-15L versus 70.8% for NASHA. LFS responder rates exceeded 60% through 1 year with VYC-15L. Perioral lines severity improved for 65.4% and 66.2% of VYC-15L subjects at Month 3 and Year 1, respectively. At Month 3, 96.1% and 88.2% of subjects reported improvement in FACE-Q Satisfaction With Lips and Satisfaction With Lip Lines, respectively. Severe injection site responses were reported less frequently with VYC-15L than NASHA. CONCLUSION:VYC-15L was safe and effective for lip and perioral enhancement, with treatment effects lasting through 1 year.
RCT Entities:
BACKGROUND: VYC-15L (Juvéderm Volbella XC) is a nonanimal crosslinked hyaluronic acid (HA) gel with lidocaine. OBJECTIVE: To evaluate the safety and effectiveness of VYC-15L for lip and perioral enhancement versus a nonanimal stabilized HA with lidocaine (Restylane-L; NASHA). METHODS: This prospective multicenter study randomized 225 adults with minimal, mild, or moderate lip fullness on the validated 5-point Allergan Lip Fullness Scale (LFS) to treatment with VYC-15L or NASHA; optional touch-up was administered 30 days later. Subjects were followed for 1 year. The primary effectiveness end point was noninferiority of VYC-15L versus NASHA by mean change in LFS score from baseline to Month 3. RESULTS: The primary end point was met. At Month 3, LFS responder rates were 80.3% for VYC-15L versus 70.8% for NASHA. LFS responder rates exceeded 60% through 1 year with VYC-15L. Perioral lines severity improved for 65.4% and 66.2% of VYC-15L subjects at Month 3 and Year 1, respectively. At Month 3, 96.1% and 88.2% of subjects reported improvement in FACE-Q Satisfaction With Lips and Satisfaction With Lip Lines, respectively. Severe injection site responses were reported less frequently with VYC-15L than NASHA. CONCLUSION: VYC-15L was safe and effective for lip and perioral enhancement, with treatment effects lasting through 1 year.
Authors: Maarten J Ottenhof; Inge J Veldhuizen; Lusanne J V Hensbergen; Louise L Blankensteijn; Wichor Bramer; Berend Vd Lei; Maarten M Hoogbergen; René R W J Hulst; Chris J Sidey-Gibbons Journal: Aesthetic Plast Surg Date: 2022-06-28 Impact factor: 2.326
Authors: Alexander Rivkin; Susan H Weinkle; Bhushan Hardas; Robert A Weiss; Dee Anna Glaser; Brian S Biesman; Andrew Schumacher; Diane K Murphy Journal: Aesthet Surg J Date: 2019-03-14 Impact factor: 4.283
Authors: Dario Bertossi; Riccardo Nocini; Berend van der Lei; Philippe Magistretti; Alessandro Gualdi; Ali Pirayesh; Alberto Marchetti Journal: Plast Reconstr Surg Glob Open Date: 2021-11-24
Authors: Nestor Demosthenous; David Eccleston; Vitor Figueiredo; Luis Uva; Graeme Kerson; Michael Silberberg Journal: Aesthet Surg J Open Forum Date: 2022-05-15
Authors: Carola de la Guardia; Ada Virno; Maria Musumeci; Aude Bernardin; Michael B Silberberg Journal: Facial Plast Surg Date: 2022-02-03 Impact factor: 1.286